Evidence map›Paper›PMID 37243418›Full record

ArticleJournal of cachexia, sarcopenia and muscle2023

Urinary metabolomic biomarker candidates for skeletal muscle wasting in patients with rheumatoid arthritis.

Marianne S Oliveira, Rafaela C E Santo, Jordana M S Silva, Paulo V G Alabarse, Claiton V Brenol, Steve P Young, Ricardo M Xavier

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Leveraging Multiomic Signatures to Predict Body Composition.Advances in nutrition (Bethesda, Md.) · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Marianne S OliveiraAutoimmune Disease Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Rafaela C E SantoAutoimmune Disease Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Jordana M S SilvaAutoimmune Disease Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Paulo V G AlabarseUniversity of California, San Diego, California, USA.
Claiton V BrenolAutoimmune Disease Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Steve P YoungRheumatology Research Group, University of Birmingham, Birmingham, UK.
Ricardo M XavierAutoimmune Disease Laboratory, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Universidade Federal do Rio Grande do Sul · BRUniversity of Birmingham · GBUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is an autoimmune disease that affects the joints, leading to chronic synovial inflammation and local tissue destruction. Extra-articular manifestations may also occur, such as changes in body composition. Skeletal muscle wasting is often observed in patients with RA, but methods for assessing loss of muscle mass are expensive and not widely available. Metabolomic analysis has shown great potential for identifying changes in the metabolite profile of patients with autoimmune diseases. In this setting, urine metabolomic profiling in patients with RA may be a useful tool to identify skeletal muscle wasting.

methodsPatients aged 40-70 years with RA have been recruited according to the 2010 ACR/EULAR classification criteria. Further, the Disease Activity Score in 28 joints using the C-reactive protein level (DAS28-CRP) determined the disease activity. The muscle mass was measured by Dual X-ray absorptiometry (DXA) to generate the appendicular lean mass index (ALMI) by summing the lean mass measurements for both arms and legs and dividing them by height squared (kg/height

resultsThe total set of subjects investigated included 90 patients with RA. Most patients were women (86.7%), with a mean age of 56.5 ± 7.3 years old and a median DAS28-CRP of 3.0 (IQR 1.0-3.0). Fifteen metabolites were identified in the urine samples with high variable importance in projection (VIP scores) by MetaboAnalyst. Of these, dimethylglycine (r = 0.205; P = 0.053), oxoisovalerate (r = -0.203; P = 0.055), and isobutyric acid (r = -0.249; P = 0.018) were significantly correlated with ALMI. Based on the low muscle mass (ALMI ≤6.0 kg/m

conclusionsIsobutyric acid, oxoisovalerate, and dimethylglycine from urine samples were associated with low skeletal muscle mass in patients with RA. These findings suggest that this group of metabolites may be further tested as biomarkers for identification of skeletal muscle wasting.

Indexed as

Arthritis, RheumatoidBiomarkersFemaleHumansInflammationIsobutyratesMaleMetabolomicsMiddle AgedMuscle, SkeletalMuscular AtrophyBiomarkersIsobutyratesisobutyric acidCachexiaLoss of muscle massMetabolomicsNuclear magnetic resonanceRheumatoid arthritisSarcopenia

Identifiers

PMID37243418
PMCPMC10401545
OpenAlexW4378468615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.